ArticleAnimal cells and systems2025
Combination of dasatinib and quercetin promotes osteogenic differentiation and stemness maintenance of hPDLSCs via YAP/TAZ.
Article in Animal cells and systems, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A Review of Rejuvenation Strategies Targeting Mesenchymal Stem Cell Senescence and Their Impact on Bone Health and Regeneration.Current osteoporosis reports · 2026Review
- Dasatinib and quercetin senolytic treatment delays early onset intervertebral disc degeneration in SM/J mice.Bone research · 2026Article
- MicroRNA-mediated mechanotransduction and chondrocyte differentiation in mesenchymal stem cells.Animal cells and systems · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human periodontal ligament stem cells (hPDLSCs) are candidate seed cells for periodontal tissue regeneration. Enhancing the stemness maintenance and osteogenic differentiation potential of hPDLSCs is conducive to their role in periodontal tissue regeneration. The combination of dasatinib and quercetin, a type of senolytic, has been reported to affect cell senescence. However, whether it can regulate the osteogenic differentiation and stemness maintenance of hPDLSCs, and the related mechanisms, remain unknown. The present study analyzed the optimal concentrations of dasatinib and quercetin in combination for hPDLSCs and found that the combination of dasatinib and quercetin enhanced osteogenic differentiation and promoted the expression of stemness-related markers in hPDLSCs. The expression levels of TAZ and YAP were improved when hPDLSCs were incubated with dasatinib and quercetin. However, the osteogenesis-promoting effects of dasatinib plus quercetin were partly attenuated when TAZ was knocked down, and their effects on stemness-related markers were suppressed when YAP was inhibited. Taken together, the combination of dasatinib and quercetin promotes the osteogenic differentiation and stemness maintenance of hPDLSCs, and YAP/TAZ may be involved in this process. This combination may hold promise for improving hPDLSCs function in periodontal tissue regeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.